Table 1.

Food and Drug Administration–approved immune checkpoint inhibitors

Drug	Target	Indication
Ipilimumab	CTLA-4	Melanoma, MSI-colorectal cancer, renal-cell carcinoma
Cemiplimab	PD-1	Cutaneous squamous cell cancer
Nivolumab	PD-1	Melanoma, non–small/small-cell lung cancer, renal-cell carcinoma, classic Hodgkin’s lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-colorectal, hepatocellular carcinoma
Pembrolizumab	PD-1	Melanoma, non–small-cell lung cancer, classic Hodgkin’s lymphoma, primary mediastinal large B-cell lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, gastric cancer, cervical cancer, solid tumors with high microsatellite instability or mismatch-repair deficiency
Atezolizumab	PD-L1	Non–small-cell lung cancer, urothelial carcinoma
Avelumab	PD-L1	Merkel-cell carcinoma, urothelial carcinoma
Durvalumab	PD-L1	Urothelial carcinoma, non–small-cell lung cancer

CTLA-4, cytotoxic T-lymphocyte antigen 4; MSI, microsatellite instability; PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.